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ORIGINAL ARTICLE
Differential DNA methylation at birth associated with mental
disorder in individuals with 22q11.2 deletion syndrome
A Starnawska1,2,3, CS Hansen1,4, T Sparsø1,5, W Mazin6, L Olsen1,5, M Bertalan1,5, A Buil1,5, J Bybjerg-Grauholm1,4, M Bækvad-Hansen1,4,
DM Hougaard1,4, PB Mortensen1,7,8, CB Pedersen1,7,8, M Nyegaard1,2,3, T Werge1,5,9 and S Weinsheimer1,5
Individuals with 22q11.2 deletion syndrome (DS) have an increased risk of comorbid mental disorders including schizophrenia,
attention deﬁcit hyperactivity disorder, depression, as well as intellectual disability. Although most 22q11.2 deletion carriers have
the long 3-Mb form of the hemizygous deletion, there remains a large variation in the development and progression of psychiatric
disorders, which suggests that alternative factors contribute to the pathogenesis. In this study we investigated whether neonatal
DNA methylation signatures in individuals with the 22q11.2 deletion associate with mental disorder later in life. DNA methylation
was measured genome-wide from neonatal dried blood spots in a cohort of 164 individuals with 22q11.2DS, including 48
individuals diagnosed with a psychiatric disorder. Among several CpG sites with P-valueo10− 6, we identiﬁed cg23546855
(P-value = 2.15 × 10− 7) mapping to STK32C to be associated with a later psychiatric diagnosis. Pathway analysis of the top
ﬁndings resulted in the identiﬁcation of several Gene Ontology pathways to be signiﬁcantly enriched (P-valueo0.05 after
Benjamini–Hochberg correction); among them are the following: neurogenesis, neuron development, neuron projection
development, astrocyte development, axonogenesis and axon guidance. In addition, we identiﬁed differentially methylated CpG
sites in LRP2BP (P-value = 5.37 × 10− 8) to be associated with intellectual disability (F70–79), in TOP1 (P-value = 1.86 × 10− 7) with
behavioral disorders (F90–98), in NOSIP (P-value = 5.12 × 10− 8) with disorders of psychological development (F80–89) and in
SEMA4B (P-value = 4.02 × 10− 7) with schizophrenia spectrum disorders (F20–29). In conclusion, our study suggests an association
of DNA methylation differences at birth with development of mental disorder later in life in 22q11.2DS individuals.
Translational Psychiatry (2017) 7, e1221; doi:10.1038/tp.2017.181; published online 29 August 2017
INTRODUCTION
There is a strikingly increased risk of developing a mental disorder
among individuals diagnosed with 22q11.2 deletion syndrome
(DS) including mood disorders, anxiety disorders, attention deﬁcit
hyperactivity disorder (ADHD), autism spectrum disorder, as well
as intellectual disability (ID) and schizophrenia (SZ).1–7 It is the
most common DS in humans that occurs at a population
frequency ~ 1:3700 live births (Olsen et al., manuscript in
preparation).8–11 The syndrome is characterized by a hemizygous
microdeletion of 1.5–3 Mb of chromosome 22 and is associated
with a variety of clinical phenotypes including cardiac defects,
hypocalcemia, cleft palate, dysfunction of the immune system as
well as multiple mental disorders.12–15
The International Consortium on Brain and Behavior in
22q11.2DS has collectively described the prevalence of psychiatric
diagnoses in different age groups based on 15 clinical cohorts,
reporting a change in prevalence of mental disorders in
22q11.2DS individuals throughout the lifespan.1 In these clinically
ascertained cohorts, one-third of carriers have a below-average
intellectual level (IQ, 70–84) with adults frequently diagnosed with
more severe levels of impairment.16–18 ADHD, particularly the
inattentive type, is ~ 10 times more prevalent in children with the
deletion,19 with prevalence estimates ranging from 15.6 to 37%
across different studies.1 The prevalence of autism spectrum
disorder among individuals with 22q11.2DS also varies by study/
site/instrument used, with estimates ranging from 12.81,4 to
26.5%,1 whereas SZ spectrum disorders and major depression
rates reach as high as 41.7 and 15.8%, respectively.1 Furthermore,
population-based studies suggest that the incidence rates of
psychiatric disorders are elevated in clinically identiﬁed 22q11.2
deletion carriers relative to the general population.7,20 Notably,
odds ratio estimates of 16 or more obtained from genetic
association studies21–23 index the 22q11.2 deletion as one of the
largest risk factors for SZ spectrum disorder.
Although unbiased population-based disease risk estimates are
lacking, the frequency of psychiatric health problems in clinically
identiﬁed 22q11.2 deletion carriers certainly exceed those of the
general population.7,20 Hence, a better understanding of the
biological underpinnings for the elevated risk of mental disorders
in 22q11.2 deletion carriers will facilitate improved clinical care.
Even though most 22q11.2 deletion carriers have the long 3-Mb
form of the deletion, there is a broad variation in the development
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and progression of psychiatric disorders. This could be driven by
other genetic risk factors; however, there is no evidence of the
presence of genetic factors on the non-deleted 22q11.2 copy to
predispose these individuals to the development of, for example,
psychotic disorders.24–26 This suggests that alternative factors,
such as environmental and epigenetic factors, could contribute to
the development, onset and/or progression of psychiatric
phenotypes in 22q11.2DS individuals.
The epigenome is dynamic, changing in early development,
throughout life, and even during disease progression. In addition,
epigenetic changes have been implicated in the pathophysiology
of several psychiatric disorders including SZ, bipolar disorder,
major depressive disorder and Rett syndrome.27–35 On the basis of
this growing body of evidence, we hypothesized that already at
birth the epigenome of individuals with 22q11.2DS who have a
psychiatric phenotype differs from those who carry the same
deletion but do not have a psychiatric diagnosis. In this study, to
our knowledge, we performed the ﬁrst Epigenome-Wide Associa-
tion Study (EWAS) in neonatal blood spot samples for a large case
cohort of 22q11.2DS individuals, including 29% of individuals with
a psychiatric diagnosis. Epigenetic proﬁles in neonatal blood
samples may prove to be a useful tool to identify early on which
22q11.2 deletion carriers are at increased risk for mental disorder,
allowing for early prediction and intervention, as well as improved




This EWAS study was performed on DNA from neonatal dried blood spot
samples collected at birth on ﬁlter paper for 164 unrelated 22q11.2DS
individuals (80 females and 84 males).
The cohort’s current mean age was 14.7 years (s.d. = 6.5). Subjects were
selected from The Danish Cytogenetic Central Register, and presence of
22q11.2 deletion was identiﬁed via ﬂuorescent in situ hybridization and/or
comparative genomic hybridization array. Out of all 22q11.2DS cases
identiﬁed from the Danish Cytogenetic Central Register, 209 individuals
had a blood spot sample stored within the Danish Neonatal Screening
Biobank (DNSB), which is a part of the Danish National Biobank (those who
did not have a blood spot sample were primarily born before 1982).
Individuals were excluded from the methylation study if array quality-
control failed, genetic validation did not verify the deletion or the deletion
mapped downstream of the 22q11.2 locus and hence did not truly
represent 22q11.2DS. Type of 22q11.2 deletion was additionally conﬁrmed
with genotype data obtained from Inﬁnium PsychArray BeadChip (Illumina,
San Diego, CA, USA, data not shown), followed by copy number variant
(CNV) prediction using the PennCNV software (http://www.openbioinfor-
matics.org/penncnv/).36
Psychiatric diagnosis information was retrieved from the Danish
Psychiatric Central Register, which contains information about all
admissions to Danish psychiatric inpatient facilities since 4 January 1969
and outpatient since 1995.37 In this cohort, a total of 48 individuals (21
females and 27 males) had an ICD-10 level F diagnosis (Mental and
Behavioral Disorders), whereas 116 individuals have not had a documen-
ted current or past psychiatric diagnosis (called, respectively, psychiatric
cases and non-psychiatric controls in the primary analysis). The mean age
of individuals with psychiatric diagnosis was 16.7 years (s.d. = 6.2).
In secondary analyses, we evaluated the methylomes using further
stratiﬁcation of psychiatric diagnoses in which the psychiatric cohort was
subcategorized into four main diagnosis groups: intellectual disability (ID,
F70–79: intellectual disability, n=23), behavioral disorders (BDs, F90–98:
behavioral and emotional disorders with onset usually occurring in
childhood and adolescence, n= 12), disorders of psychological develop-
ment (PD, F80–89: disorders of psychological development, n=16) and SZ
spectrum disorders (F20–29: schizotypal and delusional disorders, n= 4;
Supplementary Figure 1). Detailed demographics for this cohort are
presented in Supplementary Table 1. Individuals with comorbid mental
disorders were included in the analyses as reﬂected by Supplementary
Figure 1.
The study was approved by the Regional Ethical Committee, The Capital
Region of Denmark, Copenhagen, Denmark (Arv&Miljø:H-B-2009-026) and
Danish Data Protection Agency (PSV-2009-07). Permissions were granted
to couple and perform population-based analyzes from the Danish
Cytogenetic Central Register, DNSB and Danish National Patient Registry
resources (established and maintained according to Danish law). The
access is granted to researchers on a case-by-case request by the
competent Danish authorities.
DNA methylation analysis
Genomic DNA was extracted from neonatal dried blood spots at the
Danish Neonatal Screening Biobank. For each individual, two disks (each
3.2 mm in diameter) were punched from their dried blood spots stored on
Whatman Specimen 903 Collection Paper (GE Healthcare Life Sciences,
Chicago, IL, USA). Genomic DNA was extracted with the use of Extract-N-
Amp Blood PCR kit (Sigma-Aldrich, St. Louis, MO, USA), without the
ampliﬁcation step. Genomic DNA was bisulﬁte-converted using the EZ-96
DNA Methylation Kit (Zymo Research, Irvine, CA, USA) according to the
manufacturer's instructions. DNA methylation from the bisulﬁte-converted
DNA was measured using the Inﬁnium HumanMethylation450BeadChip
array (Illumina) as previously described.38
Quality control of DNA methylation data was performed using tools in
R-packages ChAMP39 and minﬁ.40 Principal components analysis was
performed to identify possible outliers. All samples had o5% failed
probes. Methylation data were further normalized with the use of within-
array Functional Normalization, which regresses out the variability
explained by control probes included on the Inﬁnium HumanMethyla-
tion450BeadChip array in order to remove the technical variation.41
Normalization was performed with the ﬁrst two principal components.41
Normalization was followed by removal of probes with detP40.01 in at
least 20% of samples, cross-reactive probes, probes targeting sex chromo-
somes and probes known to overlap with common single-nucleotide
polymorphisms (SNPs) in the CEU population.42 Correction for possible
technical batch effects was performed with the Combat tool.43 Normalized
and batch-corrected methylation values were further logit-transformed.
To determine whether blood cell-composition estimates were different
between the study groups, we used the methylation data for estimation of
blood cell composition44 using the ﬂowSorted.CordBlood.450k reference
panel.45 This reference panel is based on ﬂow cytometry-sorted cord blood
cells for 17 individuals, all of whom contribute between four to seven
samples of distinct cell types. We estimated the composition of B cells, CD4
T cells, CD8 T cells, granulocytes, monocytes, natural killer cells and
nucleated red blood cells (nRBCs)) for each sample and investigated
whether there were signiﬁcant differences in cell composition between
mental disorder, ID, BD, PD, as well as SZ cases and non-psychiatric
controls with the use of t-test (for normally distributed blood cell
estimates) or Mann–Whitney test (for cell types with non-normal
distribution).
In addition, to conﬁrm the presence of the 22q11.2 deletion in each
individual, we used the DNAcopy package to call CNVs from the methyla-
tion data as described before.46 On the basis of the regions of CNVs called
on chromosome 22, we assessed the boundaries of each deletion type as
follows: common LRC22A–LRC22D (18892575–21460000 bp); nested prox-
imal deletion LRC22A–LRC22B (18892575–20330000 bp); nested central
deletion LRC22C–LRC22D (20700000–21460000 bp); and distal deletion
within LRC22D–LRC22E (21460000–23700000 bp). LRC22A–LRC22B and
LRC22C–LRC22D overlap with the LRC22A–LRC22D deletion region, but do
not overlap with each other, and the deletion within LRC22D–LCR22E is
located downstream of the LRC22A–LRC22D deletion. Boundaries of the
22q11.2 deletion depend on the probe distribution across this region as
represented on the methylation array. CNV plots for the 22q11.2 region
were visually inspected and CNVs were ﬁltered to include minimum 50
markers with minimum quality of segmentation mean threshold o − 0.3
for deletions. The CNV calls were also compared with PennCNV calls
for 22q11 region obtained from PsychArray SNP data (Illumina, data
not shown).
Statistical analysis
In this study we used the EWAS approach to determine differential DNA
methylation among 22q11.2 deletion carriers diagnosed with mental
disorder compared with carriers who do not have any current or past
mental disorder diagnosis (non-psychiatric controls; primary analysis). In
the secondary analyses, we evaluated four subclasses of most commonly
observed psychiatric diagnoses (ID, BD, PD and SZ) in the cohort and
compared these proﬁles to the non-psychiatric controls (same controls for
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each comparison). We used regression models to identify differentially
methylated probes (further referred to as DMP) and included adjustment
for sex, type of 22q11.2 deletion and age of the blood spot card to correct
for possible storage batch effects. Moreover, we investigated whether the
type of 22q11.2 deletion (LRC22A–LRC22D versus LRC22A–LRC22B or
LRC22A–LRC22D versus other) associated with altered methylation
patterns in the genome (CNV-type association analyses). These analyses
were performed with the use of linear regression models, with adjustment
for sex and age of the blood spot card. All statistical analyses were
performed using R.47 In this study we report all DMPs with uncorrected P-
valueo10− 6 (suggested genome-wide signiﬁcant threshold for EWAS48)
and annotated to genes using NCBI build hg19.
Functional analysis
Pathway analysis was performed on results from each EWAS using genes
annotated to DMPs with uncorrected P-valueo10− 5. Analyses for
enriched Gene Ontology (GO) pathways were performed using the tools
available in the WEB-based GEne SeT AnaLysis Toolkit (WEB-Gestalt).49 A
pathway was considered signiﬁcant if the Benjamini–Hochberg50-corrected
P-value for pathway enrichment was o0.05. To evaluate underlying
genetic networks of the psychiatric-associated genes identiﬁed in the
EWAS primary analysis (n=38 genes, P-valueo10− 5), we used the
GeneMANIA bioinformatics software with default parameters.51 The
GeneMANIA algorithm (version 3.4.0, http://www.genemania.org)52 utilizes
functional interaction data to create a network to illustrate putative
functional connections between genes. We used the GeneMANIA
Cytoscape 3.2.1 plugin version 3.4.0 (ref. 51) to obtain a network for the
psychiatric-associated genes identiﬁed in the EWAS primary analysis based
on the 2014-08-12 GeneMANIA human database build. This build includes
data from known genetic and physical interactions, shared protein
domains, coexpression data, as well as primary and curated molecular
interaction networks and pathways. The 'query gene-based' weighting
method was used in this study in which the top 20 predicted related genes
are assigned a score (computed using a variation of Gaussian ﬁeld label
propagation53,54). The score describes the degree of connectivity to the
input genes. The network gene pairs are then assigned a weight, which
reﬂects the strength of the interaction.
RESULTS
Characterization of the 22q11.2 deletion type
In this cohort we observed four types of 22q11.2 deletions
characterized by length and position (Figure 1). A total of 146
(~89%) individuals were found to carry the LRC22A–LRC22D
deletion, 12 (~7%) had LRC22A–LRC22B type, 6 (~4%) individuals
carried a deletion within the LRC22C–LRC22D or LRC22D–LCR22E
region (Figure 1). Among 48 individuals with psychiatric diagnosis,
44 (~92%) had LRC22A–LRC22D deletion, 4 (~8%) had deletion
within LRC22A–LRC22B or LRC22D–LCR22E region of 22q11.2, and
none had LRC22C–LRC22D deletion. These results were concor-
dant with PennCNV calls in SNP genotype data (data not shown)
and support the use of 450 K DNA methylation data for detection
of known CNVs. All samples passed quality-control and probe
quality and ﬁltering steps resulted in 420 363 probes that were
included in the regression analyses.
Estimation of blood cell composition
No signiﬁcant differences (P-value40.05) were found for B cells,
CD4 T cells, CD8 T cells, granulocytes, monocytes and natural killer
cell composition between investigated groups. The percentage of
nRBC in our sample was estimated to be extremely low (median
nRBC= 0.016, with 1st quantile 0.0079 and 3rd quantile 0.024),
which was expected, given these cells are present in cord blood,
but steadily decline to zero within the ﬁrst week of life.55 Because
of the similarity of blood cell composition across the study groups,
the estimates were not added as covariates to the regression
models.
Primary analysis: EWAS for psychiatric phenotype among 22q11.2
deletion carriers
We ﬁrst compared the methylome between deletion carriers who
had developed a mental disorder to deletion carriers with no
current or past diagnosis of mental disorder (22q11.2 non-
psychiatric controls). This primary analysis identiﬁed nine DMPs
with P-valueo10− 6 (Table 1 and Figure 2). In all, 22.2% of these
DMPs were located in gene bodies, 33.3% in intergenic regions
(IGRs), 44.4% in a region up to 1500 bp upstream from
transcription start site (TSS) in comparison with 33.5% in bodies,
23.2% in IGRs and 25.9% in up to 1500 bp TSS of probes included
for the EWAS analysis. The most signiﬁcantly associated DMPs
mapped to six genes: hypomethylation in Serine/Threonine Kinase
32C (STK32C), hypermethylation in WD and tetratricopeptide
repeats 1 (WDTC1), EF-Hand Domain Family, Member D1 (EFHD1),
nucleoporin 93 (NUP93), neural cell adhesion molecule 1 (NCAM1)
and zinc-ﬁnger MYND-type containing 10 (ZMYND10). The
remaining three associated DM probes were intergenic, including
the top associated hypomethylated DMP cg21509978 (P-
value = 8.91 × 10− 8) located in a DNaseI hypersensitivity region
on chromosome 7, located 23.6 kb away from the gene family
with sequence similarity member C (FAM20C; Table 1). Boxplots for
the probes associated in STK32C and EFHD1 are presented as
Figures 3a and b.
GO pathway analysis identiﬁed 10 signiﬁcantly enriched path-
ways (Benjamini–Hochberg-adjusted P-valueo0.05), including
neurogenesis, neuron development, astrocyte development and
axon guidance (Supplementary Table 2). Psychiatric-associated
DMPs (P-valueo10− 5) were annotated to a total of 38 genes,
which were input to GeneMANIA to identify genetic networks. The
network analysis illustrates that 36 of the 38 genes were
connected in a complex interactive network with a high degree
of coexpression and several genes with many genetic interactions,
for example, STK32C and NUP210L (Supplementary Figure 2).
Secondary analyses: EWAS of psychiatric subphenotypes
In an exploratory analysis, the 48 individuals with a psychiatric
disorder were further characterized by psychiatric subclassiﬁcation
and secondary EWAS were performed to identify DMPs for the
four most abundant diagnoses (ID, BD, PD and SZ), summarized in
Table 1 and Figure 3. Nine DMPs were associated with ID including
the most signiﬁcant DMP mapping to Low Density Lipoprotein
Receptor-Related Protein 2 Binding Protein (LRP2BP, Figure 3c).
Two DMPs were associated with BD, one of which mapped to Type
I DNA Topoisomerase (TOP1) and the other to an IGR on
chromosome 14 (Figure 3d).
Eight DMPs associated with PD with the top associated DMPs
mapping to Nucleoporin 210 kDa-Like (NUP210L) and Nucleoporin
93kDa (NUP93; Figure 3e). Two DMPs located 9 bp apart mapped
to Nitric Oxide Synthase Interacting Protein (NOSIP;
Supplementary Figure 4).
Three DMPs were associated with SZ, including two in known
genes, Heat Shock Factor Binding Protein 1 (HSBP1) and Sema
Domain, Immunoglobulin Domain, Transmembrane Domain And
Short Cytoplasmic Domain (Semaphorin), 4B (SEMA4B), whereas
the other maps to an IGR of chromosome 4 (Figure 3f).
There was no overlap of signiﬁcant DMPs between the
subpsychiatric diagnoses; however, several DMPs overlapped
across the diagnoses when considering P-valueo10− 5
(Supplementary Figure 5). GO pathway analysis for the ID DMPs
identiﬁed enrichment in pathways involved in myoblast differ-
entiation. There were no GO pathways signiﬁcantly enriched in
BD, PD or SZ EWAS analyses.
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Figure 1. Top panel: Overview of 22q11.2 deletion types obtained by CNV calling from 450 K DNA methylation array for all 164 individuals
included in the sample arranged by 22q11.2 deletion type. Horizontal gray lines marked A–E indicates boundaries of different 22q11.2
deletion types. ROI indicates 22q11.2 deletion region of interest as deﬁned by genotyping data for these individuals. Bottom panel: Overview
of RefSeq genes (hg19) located in the region of 22q11.2 deletion. Orange color indicates genes transcribed from the sense strand; blue color
indicates genes transcribed from the antisense strand. CNV, copy number variant.
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Figure 2. Overview of signals and corresponding effect sizes for results obtained from EWAS of 22q11.2DS individuals with psychiatric
phenotype versus controls. Each dot represents one probe used in the EWAS analysis. (a) Manhattan plot depicting signiﬁcance levels for all
probes included in the primary analysis (blue line marks − log10(1e− 05), red line marks − log10(5e− 08) signiﬁcance level); (b) volcano plot
depicting effect sizes compared with the signiﬁcance levels of all probes included in the primary analysis. DS, deletion syndrome; EWAS,
Epigenome-Wide Association Study.
Table 1. Overview of ﬁndings with P-valueo10− 6 obtained from EWAS analysis of psychiatric phenotypes in individuals with 22q11.2DS
Probe ID P-value CHR bp Gene Genomic feature
Psychiatric (n= 48) versus controls (n= 116) cg21509978 8.91E− 08 7 169 560 NA IGR—open sea
cg23546855 2.15E− 07 10 134 068 039 STK32C Body—shelf
cg22877639 3.59E− 07 22 51 023 896 NA IGR—shelf
cg01396034 5.07E− 07 1 27 623 367 WDTC1 Body—open sea
cg04143750 7.39E− 07 2 233 497 656 EFHD1 TSS1500—shore
cg09308553 8.09E− 07 16 56 763 573 NUP93 TSS1500—shore
ch.12.31424680R 8.39E− 07 12 31 533 413 NA IGR—open sea
cg02126412 8.40E− 07 11 112 831 938 NCAM1 TSS200—shore
cg04322105 8.97E− 07 3 50 383 309 ZMYND10 TSS200—island
Intellectual disability (n= 23) versus controls (n= 116) cg02970919 5.37E− 08 4 186 300 945 LRP2BP TSS1500—open sea
cg25743026 1.30E− 07 6 107 194 450 NA IGR—open sea
cg08540622 3.41E− 07 11 59 806 898 PLAC1L TSS1500—open sea
cg22052566 3.68E− 07 7 151 079 167 WDR86 Body—island
cg07941927 6.13E− 07 13 100 644 041 NA IGR—shore
cg07186765 7.05E− 07 7 30 633 504 GARS TSS1500—shore
cg11571263 7.56E− 07 6 90 121 836 RRAGD 5′ UTR—island
cg24062754 7.87E− 07 5 175 965 158 RNF44 TSS1500—shore
cg06597895 8.00E− 07 3 44 935 097 TGM4 Body—open sea
Behavioral disorders (n= 12) versus controls (n= 116) cg01000937 7.77E− 08 14 30 730 636 NA IGR—open sea
cg00109062 1.86E− 07 20 39 655 980 TOP1 TSS1500—shore
Disorders of psychological development (n= 16)
versus controls (n= 116)
cg03352427 1.67E− 08 1 154 127 523 NUP210L 1stExon—open sea
cg09308553 6.00E− 08 16 56 763 573 NUP93 TSS1500—shore
cg01764082 1.43E− 07 9 98 784 014 NCRNA 00092 Body—island
cg04355077 5.12E− 07 19 50 059 946 NOSIP Body—island
cg22489957 8.26E− 07 6 28 921 805 NA IGR—open sea
cg19696083 8.50E− 07 12 54 438 419 HOXC4 5′ UTR—shelf
cg21292909 8.86E− 07 19 50 059 937 NOSIP Body—island
cg08427305 9.99E− 07 19 30 165 133 PLEKHF1 Body—island
Schizophrenia (n= 4) versus controls (n= 116) cg12815697 1.19E− 20 16 83 841 917 HSBP1 Body—island
cg13298070 1.55E− 10 4 189 580 507 NA IGR—island
cg19331221 4.02E− 07 15 90 728 027 SEMA4B TSS200—island
Abbreviations: 1stExon, ﬁrst exon of the gene; 5′ UTR, 5′ untranslated region; Body, gene body; CHR, chromosome; DS, deletion syndrome; EWAS, Epigenome-
Wide Association Study; IGR, intergenic region; island, CpG island; open sea,44 kb up- or downstream from CpG island; NA, not available (no gene maps to
this CpG site); shelf, 2–4 kb up- or downstream from CpG island; shore, 0–2 kb up- or downstream from CpG island; TSS, transcription start site (200—up to 200
bp upstream from TSS,1500—up to 1500 bp upstream from TSS). Annotation based on UCSC (genome.ucsc.edu) GRCh37/hg19 reference.
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CNV-type association analysis
Gene dosage may inﬂuence DNA methylation either locally at the
CNV or elsewhere in the genome; hence, we evaluated whether
the speciﬁc type of 22q11.2 deletion associates with a distinctive
DNA methylation signature independent of the psychiatric
diagnosis. We identiﬁed 107 DMPs in the comparison of
methylomes between the LRC22A–LRC22D and LRC22A–LRC22B
deletion, 100 of which were located on chromosome 22
(Supplementary Table 3) and mapped to 16 known genes at the
LRC22C–LRC22D deletion region (Figure 4a, located in boundaries
C–D) including Zinc Finger Protein 74 (ZNF74), Scavenger Receptor
Class F, Member 2 (SCARF2), Mediator Complex Subunit 15
(MED15), Synaptosomal-Associated Protein, 29 kDa (SNAP29) and
Apoptosis-Inducing Factor, Mitochondrion-Associated, 3 (AIFM3).
Effect sizes of the ﬁndings located on chromosome 22,
presented as difference of the mean methylation between
individuals with LRC22A–LRC22D and those with LRC22A–LRC22B
deletion, are presented at Figure 4b. Most of the DMPs mapping
to chromosome 22 were within 200 bp of the TSS (200TSS) or in
the gene body, and were located in a CpG Island (Figure 4c). The
distribution of 107 DMPs in TSS and IGRs was different than
expected by random with 31.8% of DMPs located in TSS200 in
comparison with only 11.4% of probes targeting this genomic
feature in this EWAS. In turn, 7.5% DMPs were located in IGRs in
comparison with 23.2% of probes targeting this genomic feature.
No other striking differences were observed in the distribution of
107 DMPs across other genomic features.
A total of 11.2% of DMPs (versus 14.5% probed) were located in
TSS1500, 32.7% of DMPs (versus 33.5% probed) were in gene
bodies, 7.5% DMPs (versus 9.0% probed) were in 5′ untranslated
regions (UTRs), 4.7% DMPs (versus 3.5% probed) were in 3′ UTRs
and 4.7% DMPs (versus 4.8% probed) were in the ﬁrst exon. Five of
the seven additional DMPs for LRC22A–LRC22D versus LRC22A–
LRC22B CNV type mapped to the following loci: chromosome 5
open reading frame 38 (C5orf38), N-acyl phosphatidylethanola-
mine phospholipase D (NAPEPLD), tubulin alpha 3c (TUBA3C) and
cg20496134 in Family With Sequence Similarity 128B (FAM128B),
also known as Mitotic Spindle Organizing Protein 2B (MZT2B), and
located 4668 bp upstream cg10992590 located in the same intron
of MZT2B, but also overlapping with Sphingomyelin Phosphodies-
terase 4, Neutral Membrane (Neutral Sphingomyelinase-3; SMPD4;
Supplementary Figures 6A–G).
Comparison of the LRC22A–LRC22D deletion with all other
deletion types resulted in 112 DMPs (Supplementary Table 4); the
Figure 3. Overview of DNA methylation values for the highly associated CpG sites in EWAS of psychiatric diagnosis, site in STKC32 (P-
value= 2.15 × 10− 7; a) and in EFHD1 (P-value= 7.39 × 10− 7; b); intellectual disability, site in LRP2BP (P-value= 5.37 × 10− 8; c); behavioral
disorders, site in TOP1 (P-value= 1.86 × 10− 7; d); disorders of psychological development, site in NUP210L (P-value= 1.67 × 10− 8; e);
schizophrenia, site in SEMA4B (P-value= 4.02 × 10− 7; f). EWAS, Epigenome-Wide Association Study.
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majority of these (n= 99) overlapped with the DMPs identiﬁed
from LRC22A–LRC22D versus LRC22A–LRC22B analysis. Overlap of
these DMPs was expected, as the majority of deletions present in
the ‘other’ category are the LRC22A–LRC22B type, which is driving
the differential methylation signal. After addition of other types of
CNV to the sample, we observed an increase in signiﬁcance level
of DMPs located in LRC22A–LRC22B and decrease of signal in the
LRC22C–LRC22D region.
DISCUSSION
Epigenetic studies performed in samples collected at birth have
the potential to reveal neonatal predictors of mental disorders
before manifestation of their clinical symptoms. In this study, to
our knowledge, we performed the ﬁrst EWAS in a large cohort of
individuals with 22q11.2DS and report that differential DNA
methylation in neonatal blood spots is associated with mental
disorders manifested later in life. After careful inspection of
methylation data and application of standard quality-control
measures, we found the neonatal blood spots to be a useful
resource to evaluate the whole-genome DNA methylation proﬁles,
and also conﬁrm the 22q11.2 deletion for each individual in the
cohort as documented in the Danish Cytogenetic Central Register.
Even though the estimation of the deletion boundaries depended
on the probe distribution on the methylation array, we observed
that the boundaries assessed independently by methylation array
and genotyping array gave very comparable results, thus
supporting CNV calling from array-based methylome data as
previously proposed.46 Distribution of different 22q11.2 deletion
types was comparable between those with mental disorder and
those without, with one exception that LRC22C–LRC22D deletion
was not observed among individuals with diagnosed mental
disorders. However, since only three individuals harbor the
LRC22C–LRC22D deletion, larger studies of 22q11.2DS will be
able to provide evidence whether this deletion type inﬂuences risk
of mental disorders. Frequencies of 22q11.2 deletion subtypes
observed in this cohort were comparable to previously published
estimates.56
We identiﬁed nine DMPs at birth that were differentially
methylated between 22q11.2DS individuals with a psychiatric
diagnosis and those without a psychiatric diagnosis. Several of the
DMPs map to genes that have been previously implicated in
mental disorders. For example, we observed hypomethylation of a
CpG site in an intron of STK32C in individuals with a psychiatric
diagnosis. A CpG site in STK32C located 31 235 bp from the one
we report here was previously reported to be associated with
adolescent depression and major depressive disorder in a recent
methylome study of buccal cells from monozygotic twins.33 The
signal was additionally replicated in post-mortem cerebellum
tissue from an independent cohort of cases suffering from major
depressive disorder and unaffected individuals.33 Interestingly,
22q11.2DS individuals are known to have increased risk of
developing major depressive disorder, with prevalence at
adolescence estimated to reach 9%.1 Thus, the differential
methylation detected at birth in STK32C may contribute to the
risk of mental disorder for 22q11.2DS individuals. STK32C is known
to be highly expressed in the human brain, with highest
expression levels reported in the cerebellum and frontal
cortex.57
Interestingly, a recent study conﬁrmed that DNA methylation
across STK32C is highly predictive of cell-type-speciﬁc (neuronal
versus glial cells) gene expression proﬁles.58 Thus, even though
the speciﬁc function of this kinase is still unknown, it can be
speculated that it has a role in cellular differentiation or cell-type
speciﬁcity in the brain. In addition, using the Blood Brain DNA
Methylation Comparison Tool (http://epigenetics.iop.kcl.ac.uk/
bloodbrain/),59 which has information on DNA methylation in
blood and four brain regions, we found that the CpG site of
interest (cg23546855) in STK32C is highly methylated in cerebel-
lum samples and blood, which was consistent with results in our
study (mean methylation of cg23546855 = 0.94 in our sample).
However, even though cg23546855 is highly methylated in both
cerebellum and blood, it needs to be further investigated if
methylation level of this site also co-varies between these tissues
and how it relates to brain gene expression levels.
We also observed hypomethylation of EFHD1 to be associated
with mental disorder. Expression levels of EFHD1 are progressively
Figure 4. Overview of results located on chromosome 22 from CNV
EWAS comparing methylome proﬁles of 22q11.2 cases with
LRC22A–LRC22D versus LRC22A–LRC22B deletion type. Overview
of P-values is presented in a, effect sizes in b and genomic and CGI
context of ﬁndings associated in LRC22C–LRC22D region in c.
Horizontal blue lines on a, b indicate boundaries of different
22q11.2 deletion types (lines A–D: LRC22A–LRC22D; A and B:
LRC22A–LRC22B; C and D: LRC22C–LRC22D; D and E: LRC22D–
LRC22E). CNV, copy number variant; EWAS, Epigenome-Wide
Association Study.
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increasing in the cerebrum and cerebellum during neuronal
differentiation in mouse postnatal development.60 Interestingly,
EFHD1 is among 108 loci signiﬁcantly associated with SZ in a large
genome-wide association study performed in 36 989 SZ cases and
113 075 controls.61 EFHD1 was among other genes driving the
signal for signiﬁcant pathway enrichment analyses, where
neurogenesis and neuron projection development GO pathways
were found to be signiﬁcantly enriched. Since 22q11.2DS is
associated with changes in brain volume and widespread
alterations in brain anatomy, identiﬁcation of differential methyla-
tion of genes involved in neurogenesis and neuronal projection
can provide a putative mechanism for these alterations.62 In
addition, several other genes that function in these pathways
were differentially methylated: glial cell-derived neurotrophic
factor (GDNF), stress-induced-phosphoprotein 1 (STIP1) and neural
cell adhesion molecule 1 (NCAM1), which has a well-established
role in neurodevelopment and synaptic plasticity.63–65 Interest-
ingly, a recent SZ study reported hypomethylation of NCAM1 in a
post-mortem prefrontal cortex to be the most disorder-associated
ﬁnding.66 These results point to a potential link between DNA
methylation of genes involved in neuronal development and
mental disorder diagnosis later in life. Indeed, several genes in our
study function in pathways involved in neurodevelopment and
neurogenesis, which supports previous studies that suggested
that mental disorders have an early neurodevelopmental compo-
nent and methylomic abnormalities may be responsible for these
effects.35,67,68
It is unknown whether the DNA methylation differences
observed in this study of birth blood samples will remain stable
over time until the onset of disorder, as methylation is dynamic
throughout development.69,70 In a recent study that investigated
the epigenetic proﬁles of ADHD symptom trajectories,71 differ-
ential methylation signals observed at birth in blood were no
longer signiﬁcantly associated with ADHD trajectories at the age
of 7. These results suggest that some epigenetic signatures may
be detectable only at speciﬁc developmental stages. On the basis
of the study by Walton et al.,71 we could hypothesize that the birth
DNA methylation signatures reported in our manuscript may be
unique for this developmental stage and reﬂect only early
changes in the methylome that contribute to risk of developing
a psychiatric disorder. Future 22q11 studies including a long-
itudinal collection of blood (for example, at birth, at diagnosis and
at follow-up) will facilitate the identiﬁcation of methylation
signatures present at birth that remain stable risk markers for
mental illness.
In this study we also performed analyses of subphenotypes of
mental disorders in the 22q11.2DS cohort. We observed signiﬁcant
hypomethylation of the CpG site in the 1500TSS region of the
LRP2BP gene in individuals with ID. LRP2BP is most highly
expressed in the pituitary gland, as well as in cerebellum, and
acts as an adapter that regulates LRP2 receptor function.57,72
Mutations in the LRP2 gene have been associated with forebrain
malformations,73 autism spectrum disorder74 and mild ID.75
Moreover, genetic mutations in the LRP2 gene are known to
cause Donnai–Barrow syndrome76 characterized by agenesis of
the corpus callosum, developmental delay, as well as mild to
moderate ID.77
Analysis of BDs led to the identiﬁcation of differential methy-
lation in the 1500TSS region of TOP1, an enzyme responsible for
altering the topology of DNA.78 Inhibition of TOP1 in mouse
neurons results in decreased expression of exceptionally long
genes, caused by impaired transcription elongation, many of
which are known to be autism spectrum disorder candidate
genes.79
In EWAS of disorders of psychological development we
observed hypomethylation of two probes located in a CpG island
of NOSIP, which is critical for brain and craniofacial development
in mice and is a candidate gene for SZ61 and holoprosencephaly, a
common developmental disorder in humans.80 In addition, NOSIP
interacts and colocalizes with neuronal nitric oxide synthase
(nNOS) to regulate its distribution and activity.81 Knockout of nNOS
in mice results in a striking increase in behavioral abnormalities
including aggressive and excess sexual behaviors.82 NOSIP and
nNOS are concentrated in neuronal synapses and overexpression
of NOSIP was shown to reduce the availability of nNOS in terminal
dendrites.81 Hence, our observations support a role for NOSIP
regulation in psychological developmental disorders.
Despite the fact that this 22q11.2 cohort is relatively young and
only four individuals have been diagnosed with SZ, we observed
hypermethylation at a CpG site located in the 200TSS region of
SEMA4B associated with this phenotype. The gene has low
expression levels in adult brain;57 however, Sema4B is reported
to have a crucial role in glutamatergic and GABAergic synaptic
development in cultured hippocampal neurons, which may
contribute to SZ.83
In this study we also considered the inﬂuence of 22q11.2
deletion type on the methylation landscape and observed a gene-
dosage effect on the methylation proﬁle speciﬁcally at the local
22q11.2 region. Interestingly, 93.5% of the DM probes (P-
valueo10− 6) associated with CNV type (LRC22A–LRC22D versus
LRC22A–LRC22B) mapped to the region on chromosome 22 where
the LRC22C–LRC22D deletion occurs. LRC22C–LRC22D is the
region on chromosome 22 that distinguishes LRC22A–LRC22B
deletion type from the LRC22A–LRC22D. As individuals carrying
the hemizygous LRC22A–LRC22D deletions are missing one copy
of all genes in the region, there appears to be a gene-dosage
effect on the methylation proﬁle speciﬁcally at the local 22q11.2
region.
The effect of CNV on DNA methylation has not been well
studied. However, Strong et al.84 reported a similar observation
with symmetrical dose-dependent DNA methylation proﬁle in
children with deletion or duplication of 7q11.23. We observed that
DMPs from this analysis are over-represented in 200TSS and
under-represented in IGRs. In addition, when we characterized
differential methylation between the LRC22A–LRC22D versus all
other 22q11.2 deletion types, there was a marked decrease in the
number of DM probes at the LRC22C–LRC22D site and an increase
in the DM probes at the LRC22A–LRC22B deletion site. Thus, even
with limited number of individuals in this cohort who carry
LRC22D–LRC22E, we detect differences that enable us to speculate
that CNVs may cause a local shift in the methylome pattern. This
may be a compensatory mechanism for the loss of gene dosage at
the site. Future studies including more individuals who carry the
atypical 22q11.2 CNVs and non-22q11.2DS controls will be needed
to elucidate the biological effect of CNV on local methylome
patterns.
Moreover, seven additional CpG sites not located on chromo-
some 22 were associated with the 22q11.2 deletion type, two of
which mapped to MZT2B on chromosome 2 and NAPEPLD on
chromosome 7. MZT2B encodes a protein essential for mitotic
spindle assembly by centrosomal recruitment of γ-tubulin.85
NAPEPLD encodes an enzyme that catalyzes formation of
N-acylethanolamines utilized as signaling molecules in the
nervous system,86 and is primarily expressed in the brain,
especially in the cerebral hemisphere and cerebellum.57
Although the models used in this study included adjustment for
potential confounders such as blood spot storage time, sex and
22q11.2 deletion type, this study has several limitations. First,
methylation patterns are tissue-speciﬁc; thus, the methylation
differences observed in blood spots at birth may serve as a marker
for phenotypic risk but may not reﬂect the brain methylome, nor
deﬁne the biological development and/or progression to mental
disorder. DNA methylation patterns are also inﬂuenced by blood
cell composition and gestational age, as reported in umbilical cord
blood studies.87 Despite the fact that none of the DMPs reported
in this study overlapped with genes reported to associate with
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gestational age,87 it should be noted that the HumanMethyla-
tion27 BeadChip array (Illumina) may be not robust enough to
identify all genes associated with gestational age. In addition, birth
complications can result in negative outcomes that increase the
risk of mental disorders,88 as well as impact the epigenome.89
However, information on pregnancy and birth complications was
unavailable for our cohort; thus, future studies will be necessary to
assess the relation between birth complications, DNA methylation
signatures and mental disorders.
In addition, although 29% of the individuals in this 22q11.2
cohort have a diagnosed mental disorder, more are likely to
experience future onset of mental illness. For example, in our
sample only 2% of individuals have been diagnosed with SZ. The
cohort is quite young and many have not yet reached the mean
age of SZ onset; thus, we expect more cases to develop the
disorder later in life and future analyses shall include re-evaluation
of the adult cohort.3,90,91 In addition, because of sampling bias and
differences in information collection methods, it is noteworthy
that the psychiatric case group in this study is likely to represent
the more severe cases of mental disorders and these phenotypes
may be discrepant from other reports. For example, the
percentage of cases with ID (14%) was relatively low in
comparison with the reported 51% in the literature.4 We obtained
psychiatric diagnosis information from the Danish Psychiatric
Central Register, which is based on hospitalization record, whereas
in the study by Niklasson et al. the severity of ID was extracted
from neuropsychiatric assessments and questionnaires.4 In addi-
tion, because of the high heterogeneity of mental disorders
among 22q11.2 cases, dissection of the cohort into the most
common psychiatric phenotypes led to a very small sample size
for these secondary analyses, which reduced the power to identify
differential methylation, and could lead to possible identiﬁcation
of false-positives. With this limitation, results from the secondary
analyses should be considered as preliminary; however, further
collection of neonatal samples from 22q11.2 deletion carriers will
allow for an increase in sample size and statistical power and will
permit validation of our ﬁndings in an independent cohort
In conclusion, we report evidence of genome-wide signiﬁcant
methylation differences for mental disorder in 22q11.2DS. The
genes were enriched with those involved in neurogenesis,
nervous development and neuron projection development. We
also detected alterations in genome-wide DNA methylation
patterns associated with the type of 22q11.2 deletion. Our data
suggest that altered DNA methylation measured at birth may be a
useful approach to identify genes that contribute to the
pathophysiology of mental disorders. Future epigenetic studies
of an independent 22q11.2DS cohort will be required to replicate
these EWAS ﬁndings and longitudinal studies would complement
this research to identify early epigenetic biomarkers for mental
disorders.
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